ArticleUrologic oncology2025
Risk of de novo prostate cancer diagnosis after solid organ transplant: A retrospective claims-based matched cohort study.
Article in Urologic oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prostate cancer initially misdiagnosed as prostatic abscess in a 36-year-old kidney transplant recipient.Current therapeutic research, clinical and experimental · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionImmunosuppression in solid organ transplant patients raises concerns for de novo cancer development. However, research has been limited by small sample sizes or lack of matching. This study used a claims database to assess risk of prostate cancer in transplant patients compared to the general population.
methodsThe TriNetX Research Network was queried for men without history of prostate cancer who underwent solid organ transplant (kidney, heart/lung, liver, or pancreas) between ages 50-59, 60-69, and 70-79. Transplant patients were matched by age and PSA-screening to controls who did not have a history of solid organ transplant or prostate cancer.
resultsAfter matching, there were 59,701 patients in each arm for the 50-59 cohort, 66,801 per arm for the 60-69 cohort, and 34,187 per arm for the 70-79 cohort. For all 3 transplant cohorts, the relative risk of a prostate cancer diagnosis was significantly lower than for their age-matched controls through 10 years after solid organ transplant. When stratified by organ type, men with kidney or liver transplants had a lower risk of prostate cancer compared to controls. Men with heart/lungs or pancreas transplants had risk similar to controls.
conclusionsThe decreased long-term risk of a prostate cancer diagnosis in transplant patients compared to matched controls highlights the likely value of pretransplant PSA screening and the lack of any clearly increased prostate cancer risk related to immunosuppressive medication in this population. Additional studies are needed to clarify any relationship between prostate cancer and transplantation and post-transplant screening recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.